title: Ant venom immunotherapy in Australia: the unmet need.
abstract: Jack jumper ant (JJA) venom allergy is an important cause of anaphylaxis in south-eastern Australia. The efficacy and real-world effectiveness of JJA venom immunotherapy (VIT) to prevent anaphylaxis in allergic patients are now well established, with an evidence base that is at least equivalent to that supporting VIT for allergy to other insect species. The tolerability and safety of JJA VIT are comparable with those of honeybee VIT.
authors.affiliation: John James Medical Centre, Canberra, ACT, Australia. simon.brown@uwa.edu.au.
authors.forename: Raymond J
authors.initials: RJ
authors.lastname: Mullins
authors.affiliation: University of Western Australia and Royal Perth Hospital, Perth, WA, Australia.
authors.forename: Simon G A
authors.initials: SG
authors.lastname: Brown
mesh_terms: D000707:Anaphylaxis / Q000276:immunology* / Q000517:prevention & control*; D000862:Ant Venoms / Q000009:adverse effects* / Q000276:immunology / Q000627:therapeutic use*; D001315:Australia; D003888:Desensitization, Immunologic / Q000379:methods* / Q000639:trends*; D019317:Evidence-Based Medicine; D006301:Health Services Needs and Demand / Q000639:trends*; D006801:Humans; D006967:Hypersensitivity / Q000188:drug therapy* / Q000276:immunology; D012307:Risk Factors
chemical_list: D000862:Ant Venoms